Stories about Diabetic neuropathy

Subscribe to Diabetic neuropathy

01.12.2020 – 09:12

Grünenthal Group
Grünenthal agrees to acquire European rights to CRESTOR [TM] (rosuvastatin) from AstraZeneca

Aachen, Germany (ots) - Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced that it has agreed to acquire the European rights (excluding Spain and the UK) to CRESTOR[TM] (rosuvastatin) and its associated brands for a total consideration of up to US$ 350 million. CRESTOR(TM) is among the leading statin products in Europe and is ...

more
21.07.2020 – 16:00

Grünenthal Group
Grünenthal and Averitas Pharma Announce U.S. FDA Approval of QUTENZA® for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy of the Feet

Aachen, Germany & Morristown, N.J. (ots) - - Neuropathic pain associated with diabetic peripheral neuropathy is a progressive and debilitating complication of diabetes that will affect approximately more than 5 million Americans in 20201. - QUTENZA® is the first and only topical, non-systemic, non-opioid pain ...

more
18.12.2019 – 14:07

Grünenthal Group
Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin) 8% Patch for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

Morristown, N.J. (ots) - · PDUFA date set for July 19, 2020 · If approved, QUTENZA would be the first topical treatment with a TRPV1 agonist indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc. and member of the ...

more
02.05.2019 – 14:00

Grünenthal Group
Five young scientists win EFIC-Grünenthal Grant 2018

Brussels/Aachen (ots) - - Five creative ideas aimed at advancing research in pain have been selected to receive funding from the prestigious EFIC-Grünenthal Grant (E-G-G) 2018. - The selected teams of young scientists will start executing there innovative projects with the ambitious objective to improve the lives of people in pain. The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have ...

more
14.11.2018 – 08:45

Grünenthal Group
Grünenthal acquires Averitas Pharma and establishes commercial footprint in the US

Aachen, Germany / Morristown, New Jersey, USA (ots) - Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the ...

more

1